Regimmune Corporation
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Regimmune Corporation sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Regimmune Corporation: 2 sponsored US clinical trials, none currently recruiting.
Regimmune Corporation sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prevention of aGVHD, with 1 trials.
Mid-pack sponsor footprint
Regimmune Corporation is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT04014790
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
NCT01379209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
How the Regimmune Corporation early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Prevention of aGVHD (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Regimmune Corporation: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Regimmune Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Regimmune Corporation page
2 registered trials is a research-attention snapshot, not an endorsement of Regimmune Corporation or any single study.
- None of Regimmune Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prevention of aGVHD is the condition Regimmune Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prevention of aGVHD trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Regimmune Corporation pipeline card: 2 registered trials from official public datasets.Report a data error.